BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18637944)

  • 1. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.
    Andersen JT; Justesen S; Fleckenstein B; Michaelsen TE; Berntzen G; Kenanova VE; Daba MB; Lauvrak V; Buus S; Sandlie I
    FEBS J; 2008 Aug; 275(16):4097-110. PubMed ID: 18637944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
    Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
    J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
    Andersen JT; Dee Qian J; Sandlie I
    Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the complex of rat neonatal Fc receptor with Fc.
    Burmeister WP; Huber AH; Bjorkman PJ
    Nature; 1994 Nov; 372(6504):379-83. PubMed ID: 7969498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.
    Magistrelli G; Malinge P; Anceriz N; Desmurs M; Venet S; Calloud S; Daubeuf B; Kosco-Vilbois M; Fischer N
    J Immunol Methods; 2012 Jan; 375(1-2):20-9. PubMed ID: 21939661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.
    Feng Y; Gong R; Dimitrov DS
    Protein Expr Purif; 2011 Sep; 79(1):66-71. PubMed ID: 21453773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport.
    Leach JL; Sedmak DD; Osborne JM; Rahill B; Lairmore MD; Anderson CL
    J Immunol; 1996 Oct; 157(8):3317-22. PubMed ID: 8871627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial expression, characterization, and disulfide bond determination of soluble human NTPDase6 (CD39L2) nucleotidase: implications for structure and function.
    Ivanenkov VV; Murphy-Piedmonte DM; Kirley TL
    Biochemistry; 2003 Oct; 42(40):11726-35. PubMed ID: 14529283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
    Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
    Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc.
    Huber AH; Kelley RF; Gastinel LN; Bjorkman PJ
    J Mol Biol; 1993 Apr; 230(3):1077-83. PubMed ID: 8478919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and phylogenetic analysis of the MHC class I-like Fc receptor gene.
    Kandil E; Noguchi M; Ishibashi T; Kasahara M
    J Immunol; 1995 Jun; 154(11):5907-18. PubMed ID: 7538537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.